ABBV · News · 20260817N
Revenue Performance and Mix
AbbVie Inc. · 2026-08-17 · Importance 47 · Surprise 22 · No source text
AbbVie reported Q1 2026 revenue growth of 12.4% year over year. Growth was driven by the neuroscience, immunology, and aesthetics portfolios. EPS exceeded expectations during the quarter, although the digest does not provide revenue amounts or segment-level dollar contributions.
Key facts
- AbbVie reported Q1 2026 revenue up 12.4% year-over-year. source
- AbbVie reported Q1 2026 EPS exceeding expectations. source
- AbbVie's Q1 2026 results were driven by growth in its neuroscience, immunology, and aesthetics portfolios. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +12.4% | AbbVie reported Q1 2026 revenue up 12.4% year-over-year. |